The Effectiveness of Meloxicam Adjuvant Therapy to Improve Cognitive Function of Schizophrenic Patients

Highlights:1. Schizophrenic patients have cognitive dysfunction.2. Meloxicam, as an adjuvant therapy, can improve function in schizophrenic patients. AbstractIntroduction: Schizophrenia is a chronic psychotic disorder triggered by genetic and environmental factors such inflammatory response. The response increases with decline. Meloxicam non-steroidal anti-inflammatory drug (NSAID) group Cyclo-oxygenase (COX-2) inhibitory activity suppress the production of cytokines. This study aimed to determine efficacy therapy patients.Methods: was quasi-experimental using single-blind, pretest–post-test design. sample size this 34 subjects who had met inclusion exclusion criteria. All samples were divided into two groups, namely treatment group, many 17 receiving additional 15 mg/day for 4 weeks, control subjects. score Cognition Rating Scale (ScoRS) assessed before after therapy. Data analysis used SPSS 25.0. In both SCoRS different.Results: there decrease that greater than group. There statistically significant difference p = 0.002 decreasing scores.Conclusion: scores.